GLP-1s and Mood: What the Regulators Concluded

In 2023, reports began circulating of suicidal thoughts in people taking GLP-1 medicines. The reports were taken seriously by exactly the institutions whose job it is to take them seriously: regulators on both sides of the Atlantic opened formal reviews. Both reviews are now finished, and this article reports what each one examined and concluded, because the conclusion deserves to be known as clearly as the original reports were.

One thing needs saying before the findings, because it frames everything after it. A review of populations is a review of populations. It can answer whether a signal shows up across millions of people; it cannot answer how any one person feels on any one month, and it was never designed to. Both halves of that sentence get their full space below. The findings first.

How the reviews began

In July 2023, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the committee usually abbreviated PRAC, began reviewing reports of suicidal thoughts and thoughts of self-injury in people taking liraglutide and semaglutide medicines. It was analyzing around 150 reports. That number is small against the millions of people using these medicines, and small is not a dismissal: adverse event reporting systems are built so that a cluster of worrying reports triggers a systematic look, and that is precisely what happened.

It is worth being clear about what opening a review means and does not mean. It is not an announcement that a problem has been found. It is a decision to check, thoroughly, using evidence of a kind individual reports cannot provide: controlled trials, large observational datasets, everything already published. The checking took time on both continents, and the results arrived separately, which is why they are reported separately here.

The European conclusion

PRAC published its conclusion on 12 April 2024. After reviewing non-clinical studies, clinical trials, post-marketing surveillance data and the available studies, the committee found that the evidence did not support a causal association between the medicines and suicidal thoughts and self-injury, and it concluded that no update to the product information was warranted.

Read that outcome precisely. The committee did not declare the medicines protective of mood, did not rate the initial reports as unfounded, and did not close the subject forever. It looked at the full body of evidence available to it and found that the evidence did not support a causal link, so the product information stayed as it was. That is a clean, scoped finding, and it is the finding Europe stands behind.

The FDA's review and what it changed

The American review ran longer and went further, and its conclusions were published in a Drug Safety Communication dated 13 January 2026. The headline sentence: the FDA's evaluation did not identify an increased risk of suicidal ideation or behavior with the use of GLP-1 RA medications.

What stands behind that sentence is worth listing, because the scale is the point. The evaluation drew on a meta-analysis of 91 placebo-controlled GLP-1 receptor agonist trials including 107,910 patients; a cohort study of 2,243,138 users comparing GLP-1 receptor agonists with alternative diabetes medicines, which found no elevated risk of self-harm; and the published observational research. Of those studies the FDA wrote, in its own summary, that the totality of these studies does not support a causal relationship.

Then came the action, and it is unusual enough to notice. The FDA requested that application holders remove the information about the risk of suicidal ideation and behavior from GLP-1 receptor agonist labeling. The products named were Saxenda, Wegovy and Zepbound. Labels rarely shed a warning; the ordinary direction is the other one. Removing one is about the strongest expression of a conclusion a regulator has available.

The line you can check yourself

Here is the detail that makes the whole story checkable by any reader, and it is unusual for a regulatory outcome to leave this kind of paper trail. Drug labels carry revision histories, sections listed with the dates they were added, changed or removed. The Wegovy label lists Suicidal Behavior and Ideation, section 5.10, as removed in 02/2026. Zepbound lists Suicidal Behavior and Ideation as removed in 02/2026. Saxenda lists Suicidal Behavior and Ideation, section 5.9, as removed in 02/2026. Three products, the same three the FDA named, the same month, all visible in the labels' own appendix of changes.

Why does this matter? Because most medication controversies end in a fog of dueling summaries, and this one ended in a documented, dated edit to the primary documents. A reader who hears conflicting things about GLP-1s and mood does not have to weigh headlines against each other. They can open any of those three labels, find the revision history, and see for themselves that a warning existed and was withdrawn after a review of the evidence. That is what a primary source looks like, and it is why the dates are reported here in full.

GLP 1 Tracker AppDoses, energy notes and side effect entries in one private place on your phone, so a conversation with a clinician starts from the record rather than from memory. Get the app

What a population finding cannot tell you

Now the harder half of the framing promised at the top. Two regulators reviewed large bodies of evidence and neither found a causal association. That is a real finding, arrived at seriously, and this article reports it plainly. And none of it tells any individual reader anything about how they feel. A review finding no population-level association is not a finding that nobody's mood changes on these medicines. Both things are true, and holding them together is the honest position.

There are also real things happening in the same weeks as the medicine that have nothing to do with any pharmacological question. Weight can come off quickly. Appetite can shrink to a fraction of what it was, and eating far less changes energy, social life and daily rhythm. Living with a chronic condition, and with the attention that a changing body draws, is its own load. None of that is a side effect in the label sense, and all of it can color a mood. The reviews covered the drug question; they did not, and could not, examine anyone's particular circumstances.

So the routing is simple and it is separate from the drug question: anyone whose mood has changed, for any reason or none, should say so to their clinician. The FDA's own advice to patients, quoted from its communication, is exactly the right register: patients should continue taking their medication as prescribed and discuss any concerns with their health care professionals. And one sentence more belongs here, without qualification: if things ever feel dark, crisis support exists and is worth reaching for. This article will not list warning signs or attempt any screening; it will simply say that reaching for help is the right move and always has been.

Neighboring subjects, honestly framed

There are subjects next to this one that readers searching for mood information are often actually looking for, and pointing at them is more useful than pretending this article covers everything. None of them explains a mood change, and they are offered as neighboring territory, not answers.

Fatigue is a listed adverse reaction on these labels, and being persistently tired colors how anyone feels; tracking energy alongside doses is covered in Tired on a GLP-1? Tracking Energy Alongside Your Doses. Stress and appetite interact in both directions with or without any medicine, and Stress, Appetite and GLP-1s: Reading Your Own Patterns is about noticing those patterns rather than explaining them. And a changed relationship with food is its own adjustment, with real emotional weather attached, which When Food Was Your Whole Social Life treats at length and with the seriousness it deserves. The regulator story reported above answers one narrow question well. These pages cover the rest of what a person on these medicines actually lives with, and a clinician covers everything else.